Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CLV-100 by Cytopeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval
CLV-100 is under clinical development by Cytopeutics and currently in Phase II for Graft Versus Host Disease (GVHD). According to...
Data Insights
CLV-100 by Cytopeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval
CLV-100 is under clinical development by Cytopeutics and currently in Phase II for Graft Versus Host Disease (GVHD). According to...